Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
复制标题
在 III 期试验中，血管生成抑制剂 IM862 对艾滋病-卡波西肉瘤无效，但显示出来自艾滋病恶性肿瘤联盟和 IM862 研究团队的高效抗逆转录病毒疗法的持续有效作用。
DOI：
10.1200/jco.2005.11.043
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
Gill,Parkash
中科院分区：
文献类型：
--
作者：
Noy,Ariela;Scadden,DavidT;Lee,Jeannette;Dezube,BruceJ;Aboulafia,David;Tulpule,Anil;Walmsley,Sharon;Gill,Parkash
